Jaguar Health Converts Preferred Stock to Common, Adjourns Annual Meeting
JAGX sits 27% above its 52-week low of $2.53 on light trading volume (0.3× avg).
Summary
Jaguar Health converted preferred stock into common shares, diluting existing shareholders by over 10% of its market cap, and further adjourned its annual meeting for shareholder review of new proxy materials.
Key Events · Financing and Capital Events · JAGX
-
Preferred Stock Conversion
Jaguar Health issued 64,668 common shares to Streeterville Capital, LLC in two privately negotiated exchange transactions (May 26 and June 1, 2026) for 7.92 shares of Series Q Preferred Stock. This conversion, valued at approximately $208,228 based on the current stock price, reduces preferred stock obligations but is dilutive to common shareholders.
-
Annual Meeting Adjourned
The 2026 Annual Meeting of Stockholders, previously adjourned on May 22, 2026, was further adjourned to June 8, 2026. This delay is to provide shareholders sufficient time to review supplemental proxy materials regarding certain proposals.
Analysis · JAGX · Life Sciences
Jaguar Health converted a significant amount of Series Q Preferred Stock into common shares, reducing its preferred stock obligations but diluting existing common shareholders by over 10% of its market capitalization. This follows a recent financial turnaround and aims to simplify the capital structure. The company also adjourned its annual meeting to allow shareholders more time to review supplemental proxy materials, likely related to previously disclosed dilutive financing proposals.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1539 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $3.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $2.53 to $152.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.